EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preclinical Theranostic Profiling of [64Cu]Cu-Acetate in Prostate Cancer

Sadaf Ghanaatgar Kasbi, Martin Savard, Céléna Dubuc, Yves Dory iD, Brigitte Guérin iD, Fernand Gobeil

Molecules · 2025

DOI: 10.3390/molecules30193957 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2025. Verfasst von Sadaf Ghanaatgar Kasbi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada. Hauptthemen laut MEDLINE: Copper Radioisotopes, Prostatic Neoplasms, Theranostic Nanomedicine, Acetates. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Movember Discovery Grant from Prostate Cancer Canada, CIHR, Canadian Institutes of Health Research Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Copper plays a critical role in cancer biology, with tumor cells exhibiting abnormal copper metabolism that drives proliferation and tumor growth. A limited number of preclinical and clinical studies have reported promising theranostic potential of copper-based radionuclides, such as 64Cu, for both diagnostic imaging and targeted radiotherapy in diverse cancers, including prostate cancer (PCa). In this work, we evaluated the cellular uptake and antitumor efficacy of [64Cu]Cu-acetate using both cellular and animal models of PCa. Uptake assays revealed that ~70% of the administered dose (10 kBq) was internalized by PC-3 cells within 24 h, predominantly localizing to the cytoplasm, with around 9% detected in the nucleus. These results were corroborated by comparable natural Cu-acetate uptake levels (at equimolar dose) in PC-3 cells, as quantified by ICP-MS. Clonogenic assays revealed a dose-dependent reduction in survival following treatment with [64Cu]Cu-acetate (3 and 6 MBq), whereas its non-radioactive counterpart [NatCu]Cu-acetate, even at excess concentrations (10 µM), had no significant effect. Ex vivo biodistribution studies showed selective tumor accumulation/retention alongside expected hepatic uptake. Clear tumor visualization was achieved using μPET imaging with [64Cu]Cu-acetate (10 MBq iv). A single higher dose (65 MBq iv) effectively reduced tumor growth in a subcutaneous PC-3 xenograft mouse model, without systemic toxicity, as evidenced by stable body weight. Together, these results further support the theranostic potential of [64Cu]Cu in PCa.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Copper RadioisotopesProstatic NeoplasmsTheranostic NanomedicineAcetatesRadiopharmaceuticalsMaleHumansAnimalsMiceCell Line, TumorTissue DistributionXenograft Model Antitumor AssaysPC-3 Cells

Stichwörter der Autor:innen

copper-64miceprostate cancerradiopharmaceuticalstheranostics

Substanzen

Copper RadioisotopesCopper-64AcetatesRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Pharmacology and Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.
  • Institute of Pharmacology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.
  • Department of Chemistry, Faculty of Sciences, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.
  • Department of Medical Imaging and Radiation Sciences, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.
  • Institut de Recherche sur le Cancer de l'Université de Sherbrooke (IRCUS), Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada.

ORCID-Profile: Yves Dory, Brigitte Guérin

Förderung

  • Movember Discovery Grant from Prostate Cancer Canada
  • CIHR
  • Canadian Institutes of Health Research Grant
  • Fonds de Recherche du Québec Santé
  • Centre de Recherche du Centre Hospitalier Universitaire de Sherbrooke

Zitieren

APA

Ghanaatgar Kasbi, S., Savard, M., Dubuc, C., Dory, Y., Guérin, B., & Gobeil, F. (2025). Preclinical Theranostic Profiling of [64Cu]Cu-Acetate in Prostate Cancer. Molecules. https://doi.org/10.3390/molecules30193957

Vancouver

Ghanaatgar Kasbi S, Savard M, Dubuc C, Dory Y, Guérin B, Gobeil F. Preclinical Theranostic Profiling of [64Cu]Cu-Acetate in Prostate Cancer. Molecules. 2025. doi:10.3390/molecules30193957

BibTeX
@article{GhanaatgarKasbi2025,
  author = {Ghanaatgar Kasbi, Sadaf and Savard, Martin and Dubuc, Céléna and Dory, Yves and Guérin, Brigitte and Gobeil, Fernand},
  title = {Preclinical Theranostic Profiling of [64Cu]Cu-Acetate in Prostate Cancer},
  journal = {Molecules},
  year = {2025},
  doi = {10.3390/molecules30193957}
}
Kostenlos starten →